This agreement focuses on treating fourth-line gastrointestinal stromal tumours (GIST) in adult patients. The territories covered under the deal include Croatia, Bulgaria, Czech Republic, Cyprus, Greece, Estonia, Latvia, The post GENESIS and Deciphera enter distribution agreement for Ripretinib appeared first on Pharmaceutical Business review.
